---
title: Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening
nct_id: NCT07332416
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Wake Forest University Health Sciences
study_type: INTERVENTIONAL
primary_condition: Gestational Diabetes
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07332416.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07332416"
ct_last_update_post_date: 2026-04-02
last_seen_at: "2026-05-12T06:40:22.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening

**NCT ID:** [NCT07332416](https://clinicaltrials.gov/study/NCT07332416)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 1300
- **Lead Sponsor:** Wake Forest University Health Sciences
- **Collaborators:** Medstar Health Research Institute, University of North Carolina, Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Conditions:** Gestational Diabetes
- **Start Date:** 2026-05
- **Completion Date:** 2027-01
- **CT.gov Last Update:** 2026-04-02

## Brief Summary

The oral glucose tolerance test (OGTT) is the standard of care in the postpartum period to screen patients with gestational diabetes mellitus (GDM) for persistent dysglycemia. However, most patients find it burdensome and dread having to do it. Adherence rates are low (18-61%), impeding initiation of follow-up care to improve diabetes-related outcomes in subsequent pregnancies and long-term.

## Detailed Description

Continuous glucose monitoring (CGM) is an appealing alternative to the OGTT because it is a low-burden, fully remote, comprehensive assessment of glycemic status. Emerging data suggest that CGM is superior to the OGTT in identifying persistent dysglycemia at 2-5 months postpartum, and preferable to the OGTT among women willing to complete both assessments in the context of a research study. This study proposes a feasibility study of postpartum CGM among patients who do not complete the standard postpartum OGTT. The study will offer CGM in a telehealth (fully remote) context to determine if it can increase adherence to postpartum glycemic screening in real-world settings. This study will (a) evaluate uptake of CGM screening, (b) characterize patients who complete CGM, complete the OGTT, or do not complete screening, and (c) monitor initiation of follow-up care after abnormal results.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 12-16 weeks postpartum
* Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy
* Oral Glucose Tolerance Test (OGTT) order placed in the medical record

Exclusion Criteria:

* Pre-gestational diabetes
* Non-English language
```

## Arms

- **Postpartum CGM** (ACTIVE_COMPARATOR) — Postpartum continuous glucose monitoring
- **Postpartum OGTT** (NO_INTERVENTION) — Postpartum oral glucose tolerance test
- **No screening** (NO_INTERVENTION) — No postpartum glucose screening

## Interventions

- **Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott** (OTHER) — Postpartum CGM

## Primary Outcomes

- **Continuous Glucose Monitor (CGM) uptake - Percentage of CGM-eligible patients** _(time frame: 20 weeks postpartum)_ — Percentage of CGM-eligible patients that return a used CGM sensor

## Locations (1)

- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.wake forest university health sciences|winston-salem|north carolina|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07332416.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07332416*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*